&nbsp;

FullDocumentClinicianResource.pdf

Oct 2021

Document

FullDocumentClinicianResource-FR.pdf

Oct 2021

Regimen

NPAC(W)+PEMB

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

New Drug Funding Program

Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer

Drugs Used:

pembrolizumab,

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

May 2024

Regimen

NIVL

Cancer Type:

Gastrointestinal,

Esophagus

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Aug 2024

Document

FormulaSedentaryTime-EN.JPG

Feb 2022

Cancer facts

New research reveals possible causes of early-onset colorectal cancer

Feb 2022

Document

FormulaSedentaryTime-FR.JPG

Feb 2022

Document

FITLabReportsPrimary.pdf

Mar 2022

Document

neilJohnson.jpg

Mar 2022

Regimen

NPAC(W)+PERTRAS(SC)

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

PERTuzumab / trastuzumab (subcut) (Unfunded),

nab-PACLitaxel (Unfunded with exceptions)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

NPAC+PERTRAS(SC)

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

PERTuzumab / trastuzumab (subcut) (Unfunded),

nab-PACLitaxel (Unfunded with exceptions)

Quick Link(s):

Regimen Monograph

May 2022

Regimen

NIVL

Cancer Type:

Genitourinary,

Bladder / Urothelial

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab - Adjuvant Treatment of Urothelial Carcinoma

Drugs Used:

nivolumab